» Articles » PMID: 34871158

COVID-19 and Hereditary Angioedema: Incidence, Outcomes, and Mechanistic Implications

Overview
Date 2021 Dec 6
PMID 34871158
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with hereditary angioedema (HAE) have been postulated to be at increased risk for coronavirus disease 2019 (COVID-19) infection due to inherent dysregulation of the plasma kallikrein-kinin system. Only limited data have been available to explore this hypothesis. To assess the interrelationship(s) between COVID-19 and HAE. Self-reported COVID-19 infection, complications, morbidity, and mortality were surveyed by using an online questionnaire. The participants included subjects with HAE with C1 inhibitor (C1INH) deficiency (HAE-C1INH) and subjects with HAE with normal C1-inhibitor (HAE-nl-C1INH), and household controls (normal controls). The impact of HAE medications was examined. A total of 1162 participants who completed the survey were analyzed, including: 695 subjects with HAE-C1INH, 175 subjects with HAE-nl-C1INH, and 292 normal controls. The incidence of reported COVID-19 was not significantly different between the normal controls (9%) and the subjects with HAE-C1INH (11%) but was greater in the subjects with HAE-nl-C1INH (19%; p = 0.006). Obesity was positively correlated with COVID-19 across the overall population (p = 0.012), with a similar but nonsignificant trend in the subjects with HAE-C1INH. Comorbid autoimmune disease was a risk factor for COVID-19 in the subjects with HAE-C1INH (p = 0.047). COVID-19 severity and complications were similar in all the groups. Reported COVID-19 was reduced in the subjects with HAE-C1INH who received prophylactic subcutaneous C1INH (5.6%; p = 0.0371) or on-demand icatibant (7.8%; p = 0.0016). The subjects with HAE-C1INH and not on any HAE medications had an increased risk of COVID-19 compared with the normal controls (24.5%; p = 0.006). The subjects with HAE-C1INH who were not taking HAE medications had a significantly higher rate of reported COVID-19 infection. Subcutaneous C1INH and icatibant use were associated with a significantly reduced rate of reported COVID-19. The results implicated potential roles for the complement cascade and tissue kallikrein-kinin pathways in the pathogenesis of COVID-19 in patients with HAE-C1INH.

Citing Articles

Deaths from Angioedema-Anaphylaxis and Covid-19.

Gray A, Ou R, Djabourian R, Augustine J, Sathyavagiswaran L Acad Forensic Pathol. 2025; :19253621251320212.

PMID: 39991143 PMC: 11843567. DOI: 10.1177/19253621251320212.


Patterns of C1-Inhibitor Plasma Levels and Kinin-Kallikrein System Activation in Relation to COVID-19 Severity.

Berra S, Parolin D, Suffritti C, Folcia A, Zanichelli A, Gusso L Life (Basel). 2025; 14(12.

PMID: 39768234 PMC: 11679851. DOI: 10.3390/life14121525.


The analysis of the effect of the COVID-19 pandemic on patients with hereditary angioedema type I and type II.

Szilagyi D, Horvath H, Andrasi N, Kempler M, Balla Z, Farkas H Sci Rep. 2023; 13(1):20446.

PMID: 37993569 PMC: 10665366. DOI: 10.1038/s41598-023-47307-1.


COVID-19 Incidence and Disease Course Among Patients at an Allergy Department.

van der Aa L, van Egmond I, van der Sluijs M, den Otter A, Bosmans N, Van Beek S Ther Adv Allergy Rhinol. 2023; 14:27534030231172391.

PMID: 37207194 PMC: 10189845. DOI: 10.1177/27534030231172391.


Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.

Zelek W, Harrison R Immunobiology. 2023; 228(3):152393.

PMID: 37187043 PMC: 10174470. DOI: 10.1016/j.imbio.2023.152393.


References
1.
Kwong E, Black N . Retrospectively patient-reported pre-event health status showed strong association and agreement with contemporaneous reports. J Clin Epidemiol. 2016; 81:22-32. DOI: 10.1016/j.jclinepi.2016.09.002. View

2.
Brickman C, Tsokos G, Chused T, Balow J, Lawley T, Santaella M . Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J Allergy Clin Immunol. 1986; 77(5):758-67. DOI: 10.1016/0091-6749(86)90425-2. View

3.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

4.
Lo M, Kemper C, Woodruff T . COVID-19: Complement, Coagulation, and Collateral Damage. J Immunol. 2020; 205(6):1488-1495. PMC: 7484432. DOI: 10.4049/jimmunol.2000644. View

5.
Garvin M, Alvarez C, Miller J, Prates E, Walker A, Amos B . A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020; 9. PMC: 7410499. DOI: 10.7554/eLife.59177. View